Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited.

Ref.: JPL/CS/2354/2026 Date: 22nd September, 2026. BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001. Scrip Code: 524731, ISIN: INE354A01013 Sub. : Intimation regarding admission of Equity Shares of the Company under “Permitted to Trade” category on National Stock Exchange of India Limited Ref : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has become aware of Circular No. NSE/CML/75748 dated 14th August, 2026, issued by the National Stock Exchange of India Limited (“NSE”), whereby NSE informed its Members that the equity shares of Jenburkt Pharmaceuticals Limited along with other companies have been permitted to trade and admitted to dealings on the Capital Market Segment of NSE under the “Permitted to Trade” category with effect from 17th August, 2026. The Company wishes to clarify that it has not applied for listing of its equity shares on NSE. The equity shares of the Company continue to be listed on BSE Limited, and their availability for trading on NSE is under the “Permitted to Trade” category pursuant to the aforesaid NSE Circular. Further, based on the records presently available with the Company, no separate communication or intimation regarding such admission under the “Permitted to Trade” category was received by the Company from NSE. The Company became aware of the aforesaid NSE Circular subsequently and is accordingly making this intimation for the information to the Exchange, shareholders and other stakeholders. This is for your information and records. Thanking you, For Jenburkt Pharmaceuticals Limited, Ashish R. Shah Sr. VP and Company Secretary and Compliance Officer